Displaying 134 (all) recruiting clinical trials.
-
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
-
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma Response and Biology-Based Risk factor-guided therapy in treating younger patients with non-high Neuroblastoma
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor ...
-
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
If you have been diagnosed with colon or rectal cancer, you may qualify to participate in a study evaluating the combination of the drugs eflornithine ...
-
Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)
The main goal of this study is to determine if deescalating chemoradiation treatment based on early tumor shrinkage at mid-treatment can result in similar cancer ...
-
HEAD START 4: NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS
If your child has been diagnosed with medulloblastoma or other central nervous system embryonal tumors, your child may qualify to participate in a study. The ...
-
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
If you or your child have been diagnosed with B-Acute Lymphoblastic Leukemia (B-ALL) that has relapsed or is refractory. Relapse means that the cancer has ... -
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
If you or your child have cancer that has become worse following treatment, or because no standard therapy exists for your type of cancer, you ... -
NMTRC14: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
If you or your child have been diagnosed with neuroblastoma that is now in remission, you or your child may be qualified to participate in ... -
Paroxysmal nocturnal hemoglobinuria (PNH) Registry
This is a non interventional registry to gather information on the clinical presentation and outcomes of patients with PNH. The PHN Registry will capture post-marketing ... -
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ...